BAYN Bayer AG

By Cecilia Butini

Bayer AG said Wednesday that its CHRONOS-3 Phase 3 study for a combination of two drugs to treat relapsed indolent non-Hodgkin's Lymphoma has met its primary endpoint of significantly prolonging patients' progression-free survival.

Progression-free survival is understood as the amount of time after treatment that a patient can live with a disease without it worsening.

The German chemicals and pharmaceuticals major said the study examined a combination of copanlisib and rituximab, and that no new safety signals were identified in the combination. Safety and tolerability of the two drugs combined were consistent with previously available data on the drugs taken individually, the company said.

Copanlisib is already approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with relapsed follicular lymphoma, Bayer said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

October 14, 2020 03:19 ET (07:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.